Roche Holding AG to Discuss Key Data Presented at SABCS 2019 Transcript
Ladies and gentlemen, welcome to the Roche analyst audio webcast and conference call from SABCS 2019. I am Sandra, the Chorus Call operator. (Operator Instructions)
At this time, it's my pleasure to hand over to Karl Mahler. Please go ahead, sir.
It's our seventh, actually, science event this year on innovation we could deliver. And I'm joined today by Alan Sandler. He is the Head of Oncology for solid tumors from the global product development. He will talk about the HER2 franchise overview -- will give us an overview.
Then we have Elena with us. Elena will talk about the triple-negative breast cancer franchise, the HER2-positive breast cancer franchise. She is the Head of Oncology for the Global Product Strategy, so the GPS part.
And last but not least, we have Stuart Lutzker with us. He's the Head of Oncology, Early Clinical Development side, and he will talk about the PI3 kinase inhibitor and the SERD.
Focusing on Slide #5. I mean we had really a very strong 2019 in terms of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
